By Gabriel Alizaidy, MD, MS
Scientific Director, Maximus
The peptide community has settled into a default position on growth hormone secretagogues that is biologically defensible but culturally overstated. The position is that you must dose fasted. Skip the meal. Wait until morning. Move the injection to pre-bed. Whatever it takes, get the peptide into a fasted body before the food blunts the response.
That advice isn't wrong. It's just incomplete, and the gap changes how you should actually dose.
Fasting does sharpen the acute pulse
The fasted-state argument starts with legitimate pharmacology. In head-to-head dosing, food blunts the acute growth hormone pulse by something like 50 to 77 percent. De Marinis 2000 measured it directly: subcutaneous GHRH gave an AUC of 1339 ± 281 fasted versus 309 ± 61 fed, and hexarelin 3010 ± 695 fasted versus 1523 ± 121 fed [1]. The driver is the free fatty acids that climb after a meal and blunt the pituitary's response to GHRH [2].
So if you can dose fasted, you should. The bigger acute pulse drives more direct fat burning, supports slow-wave sleep when timed pre-bed, and gives stronger central GH receptor activation for mood and cognition.
The honest read is simple. If fasting fits your schedule and your protocol, take it. There's no biological downside.
Where the fixation goes wrong
The problem is that the community has turned acute, single-pulse pharmacology into a universal rule for chronic protocols. That doesn't survive contact with the chronic-outcome literature.
Tesamorelin's phase III trial dosed subcutaneously "between 6 a.m. and noon" daily for 26 weeks with no fasting instruction. The result was an 81 percent rise in IGF-1 and a 15 percent drop in visceral fat [3]. The FDA-approved label has no fasting requirement at all.
Bowers 2004 is the cleanest demonstration. Continuous subcutaneous GHRP-2, infused around the clock through three meals a day, ran for 30 days [4]. Fasting morning GH fell by about half over six months, while IGF-1 rose quickly and stayed up. Same drug, two endpoints, two completely different curves.
The most vivid case is Brain 1990. Continuous subcutaneous GHRH in children for a full year, pump on 24/7 through every meal of every day, and growth velocity climbed from 4.6 to 7.0 cm per year [5]. Nobody was fasting for that.
It all points the same way. Integrated IGF-1, the thing that actually drives visceral fat loss, body recomposition, and the long-run results people are chasing, holds up in the fed state. The acute blunting happens. It just doesn't carry through to the chronic outcome.
The dissociation the field misses
The fixation persists because the community collapses three different things into one. GH pulse height, IGF-1 elevation, and actual tissue anabolism are three separate curves with three separate drivers.
Pulse height is sensitive to post-meal free fatty acids and somatostatin tone. Liver IGF-1 output integrates GH receptor activation over many hours and depends on substrate and insulin. Tissue anabolism downstream depends on local conditions at the muscle, tendon, or repair site.
Fasting optimizes the first curve. It does nothing for the second or third. Insulin and amino acids are co-permissive for IGF-1 production in the liver [6]. The clearest proof is the "GH resistance" of protein malnutrition: high GH, low IGF-1, because the liver has no substrate to act on the signal.
That is why continuous fed-state dosing still raises IGF-1. The 24-hour signal has substrate and insulin behind it across the whole interval. Cumulative exposure matters more than peak height.
The pragmatic rule
For most people it comes down to this.
If you can dose fasted, do it. You get the bigger pulse, and it costs you nothing.
If you can't, because of work, training, family, or just the reality of staying consistent for months, dose anyway. The chronic IGF-1 result that drives most of what people want doesn't require fasting.
If you can dose fasted in the morning, even better. That matches the tesamorelin protocol that produced the full clinical result, and it leaves the rest of the day open for normal eating, training, and recovery.
The real exceptions are narrow:
Pre-bed dosing for sleep, where pulse height genuinely drives slow-wave sleep.
Acute fat loss, where holding a fasted window after the injection lets you burn free fatty acids before they get re-stored.
Diagnostic GH testing, where the peak is the whole point.
Tendon and collagen repair, where the local pulse effect matters.
Long-acting analogs like CJC-1295 with DAC, where fasting is pointless because the receptor stays occupied across roughly a hundred meals from one injection [7].
For everything else, chronic recomposition, visceral fat loss, IGF-1 elevation, anti-aging tissue effects, recovery, and sarcopenia, fed-state dosing gets you the full result.
What this changes for protocol design
Peptide medicine has more moving parts than almost any other corner of performance and longevity. Different half-lives, different receptors, different downstream signaling, different relationships to food, training, sleep, and time of day. Tesamorelin and CJC-1295 with DAC share nothing but the receptor they bind. Ipamorelin and hexarelin look alike on paper and behave differently in the body. The right protocol for a 30-year-old chasing hypertrophy is not the right one for a 55-year-old with lipodystrophy or a 70-year-old fighting sarcopenia.
Single rules like "always fast," "never fast," "always pre-bed," or "always post-workout" fail because the biology is goal-dependent and population-dependent. Pulse-driven goals favor fasting. IGF-1-driven goals don't depend on it. Aging muscle needs fed-state synergy that young muscle doesn't. Insulin-resistant people respond differently than insulin-sensitive ones. Long-acting analogs take the question off the table entirely.
This is the kind of decision that benefits from someone who actually understands the physiology and isn't fear-mongering about food blunting your gains. The fasting fixation is just one example of a bigger pattern: overconfident rules applied to a field that doesn't support them.
The Maximus position
Peptide protocols deserve more than rigid rules borrowed from acute pharmacology papers. The biology is goal-dependent and population-dependent, and the guidance has to be too. Peptide medicine doesn't need more rules. It needs nuance, expert interpretation, and protocol guidance that adapts to the individual instead of overfitting to a single variable.
Fasting is a small example of the bigger point. Most of these questions have real answers, and we're always looking to find the one that works best for you.
CITATIONS
[1] De Marinis L, et al. 2000. Hexarelin vs GHRH fed/fasted subcutaneous dosing. PMID 10824712
[2] Casanueva FF, et al. 1987. Free fatty acids block GHRH-stimulated GH at the pituitary. PMID 2888782
[3] Falutz J, et al. 2007. Tesamorelin phase III in HIV-associated lipodystrophy. NEJM. PMID 18057338
[4] Bowers CY, et al. 2004. Continuous subcutaneous GHRP-2 infusion, thrice-daily meals provided. JCEM 89(5):2290. PMID 15126555
[5] Brain CE, Hindmarsh PC, Brook CG. 1990. Continuous subcutaneous GHRH 1-29 infusion for 1 year in children. PMID 2140733
[6] Thissen JP, Ketelslegers JM, Underwood LE. 1994. Nutritional regulation of IGF-1. Endocrine Reviews. PMID 7758434
[7] Teichman SL, et al. 2006. CJC-1295 with DAC pharmacokinetics. JCEM. PMID 16352683
----
Disclaimer:
The contents of this article, including, but not limited to, text, graphics, images, and other information, is for information purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. The content is not meant to be complete or exhaustive or to be applicable to any specific individual's medical condition. You should consult a licensed healthcare professional before starting any health protocol and seek the advice of your physician or other medical professional if you have questions or concerns about a medical condition. Always talk to your doctor about the risks and benefits of any treatment. Never disregard or delay seeking professional medical advice or treatment because of something you have read on this site. Maximus does not recommend, endorse, or make any representation about the efficacy, appropriateness, or suitability of any specific test, products, procedures, treatments, services, opinions, healthcare providers or other information contained herein. Maximus is not responsible for, nor will they bear any liability for, the content provided herein or any actions or outcomes resulting from or related to its use.
